Global Comparator Drug Sourcing Market Anticipated to Reach US$ 1,797.2 Million by 2032

According to a recent market study published by Growth Market Reports, titled, “Global Comparator Drug Sourcing Market By Vendor Type, By End-user, and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 1,160.2 Million in 2023 and is anticipated to expand at a growth rate of 5.2 % by 2032.

Get Sample Report @ https://growthmarketreports.com/request-sample/5063

Comparator drug sourcing is the process of acquiring reference or comparator drugs for use in clinical trials and research studies. These comparator drugs serve as essential reference points during clinical trials, enabling researchers to evaluate the safety and effectiveness of new drugs by comparing them to existing medications, placebos, or other reference point.

The process involves identifying, procuring, and supplying these comparator drugs to pharmaceutical companies, contract research organizations (CROs), and research institutions conducting clinical studies. The process also ensures that the results accurately reflect the safety and efficacy of the new treatment being investigated.

The global comparator drug sourcing market has been segmented in terms of vendor type, and end-user. On the basis of vendor type, the global comparator drug sourcing market is segmented into clinical trial supplies vendors, specialist comparator sourcing vendors, and networks/consortia. On the basis of end-user, the global comparator drug sourcing market is segmented into drug manufacturers, CMOs, academic and research institute, and others.

Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The urgency of COVID-19 vaccine and treatment development increased the demand for comparators, further straining supply chains and driving up prices. Moreover, lockdowns, transportation restrictions, and disruptions in manufacturing operations led to a certain delay and shortages in the supply of comparator drugs, affecting clinical trials and research. Regulatory agencies implemented several measures, such as allowing flexibility in comparator drug sourcing and usage in clinical trials, to mitigate supply chain disruptions. The pandemic accelerated the adoption of virtual and decentralized clinical trials, reducing the need for comparators and potentially impacting sourcing strategies. Additionally, some companies in the comparator drug sourcing market faced financial challenges, which led to mergers and acquisitions to ensure continuity of supply.

Key Takeaways from the Study:

• Players in the global comparator drug sourcing market include Almac Group; Catalent, Inc; Cencora, Inc (AmerisourceBergen Corporation); Clinical Services International (CSI); Clinigen Limited; MCKESSON CORPORATION; Myonex; Sharp Services, LLC; Thermo Fisher Scientific Inc.; TransCelerate BioPharma Inc.; and Intertek Group plc.

• On the basis of vendor type, the global comparator drug sourcing market is segmented into clinical trial supplies vendors, specialist comparator sourcing vendors, and networks/consortia.

• The specialist comparator sourcing vendors segment is expected to expand at a 5.5% CAGR during the forecast period. Clinical trials often require a variety of reference drugs for comparator arms, as they are becoming increasingly complex. Specialist vendors efficiently source and manage a diverse range of comparator drugs. Regulatory bodies across the globe impose strict quality and compliance standards for comparator drugs in clinical trials. Specialist vendors are equipped to navigate these requirements and provide regulatory support.

• On the basis of end-user, the global comparator drug sourcing market is divided into drug manufacturers, CMOs, academic and research institute, and others.

Pharmaceutical companies seek cost-effective solutions for drug manufacturing. CMOs offer cost efficiencies through economies of scale, specialized equipment, and expertise. CMOs provide flexibility for pharmaceutical companies to scale up or down production based on market demand, reducing the need for in-house manufacturing infrastructure. These factors are expected to drive the CMOs segment.

• Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The comparator drug sourcing market in Latin America held USD 37.4 Million value in 2022 and is projected to expand at a CAGR of 3.5% during the forecast period. The region is increasingly becoming a destination for clinical trials, driven by low operational costs and regulatory harmonization efforts. The growing number of clinical trials is fueling the demand for comparator drugs. Several countries in Latin America are engaged in biosimilar development. Comparator drugs are essential for conducting comparative studies to gain regulatory approvals for biosimilars.

Key Developments

• In October, 2023, Sharp Services, LLC, a global leader in commercial pharmaceutical packaging and clinical trial supply services, acquired Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectables. Moreover, Sharp Services, LLC provides fully integrated small-to-medium scale sterile injectable service offering to the biopharmaceutical industry as a result of this acquisition.

Report Scope:

Target Audience:

• Supply-side: Manufacturers, End-users/Applications

• Regulatory Side: Concerned government authorities, and other approved regulatory bodies.

  • • United States Food and Drug Administration (FDA)

    • European Union (EU)

    • Medicines and Healthcare Products Regulatory Agency (MHRA)

    • National Research Foundation of Korea (NRF)